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Pursuing our recent outcomes regarding the antifungal activity of N-substituted 1,3-thiazolidin-4-ones,
we synthesized thirty-six new derivatives introducing aliphatic, cycloaliphatic and heteroaromatic
moieties at N1-hydrazine connected with C2 position of the thiazolidinone nucleus and functionalizing
the lactam nitrogen with differently substituted (NO2, NH2, Cl and F) benzyl groups. These compounds
were tested to evaluate their minimum inhibitory concentration (MIC) against several clinical Candida
spp. with respect to topical and systemic reference drugs (clotrimazole, fluconazole, ketoconazole, mi-
conazole, tioconazole, amphotericin B). Moreover, anti-oxidant properties were also evaluated by using
different protocols including free radical scavenging (DPPH and ABTS), reducing power (CUPRAC and
FRAP), metal chelating and phosphomolybdenum assays. Moreover, for the most active derivatives we
assessed the toxicity (CC50) against Hep2 human cells in order to characterize them as multi-target
agents for fungal infections.
© 2016 Elsevier Masson SAS. All rights reserved.1. Introduction
Commensal fungi like Candida species could become opportu-
nistic pathogens causing infections whose severity depends on the
state of health of the patients, ranging from the mucocutaneous
mycosis to the more severe systemic candidiasis in those cases in
which the immune system is compromised (AIDS, cancer, trans-
plantation or broad spectrum antibiotic therapy) [1]. Recently,
many cases of candidiasis provoked by C. albicans and non-albicans
species such as C. tropicalis and C. parapsilosis have been reported
[2e5] together with several data revealing that systemic mycoses
due to C. glabrata, C. krusei and C. sake are emerging [6e9].
Nowadays the therapy for these fungal infections is mainly based
on the use of the drugs belonging to the class of azoles but, despite
their safety profile with good tolerability and bioavailability, theiradori).
served.use is leading to an increasing drug resistance and, for this reason, a
compelling need to discover new drugs with a differentmechanism
of action is required. In this regard, new compounds from the class
of thiazolidinones could be good candidates because of their anti-
mycotic effects reported in many studies [10e17]. Recently, starting
from the promising results of a scaffold of thiazol-2-yl-hydrazine
derivatives designed by our group in the past [18e22], we reported
the synthesis and the biological study of a large library of 4-
thiazolidinones bearing (cyclo)aliphatic or (hetero)aryl moieties
at N1-hydrazine and an aromatic ring at the lactam NH, demon-
strating that these compounds possessed anti-Candida activity and
most of them displayed low cytotoxicity against human cells [23].
On the basis of these interesting outcomes, we synthesized a new
library of thirty-six new antifungal drugs (1e36), functionalizing
the lactam nitrogen of the thiazolidinone nucleus using different
benzyl bromides substituted with halogens (F and Cl), nitro and
amino groups. At N1-hydrazine portion we selected four sub-
stituents which gave the best results from our previous works (2-
propane, cyclopentane, 2-acetylthiophene and 2-acetylpyridine).
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Standards Institute (CLSI) and the European Committee for Anti-
microbial Susceptibility Testing (EUCAST), we assessed the sus-
ceptibility of twenty-two clinical Candida spp. strains to our
products with the determination of their minimum inhibitory
concentration (MIC) [24]. Then, the most active compounds were
assayed to evaluate their cell toxicity (CC50) on Hep2 cells in order
to define their selectivity against Candida spp. and we figured out
that these derivatives were as cytotoxic as the well established
reference drug (clotrimazole). In addition, we screened the best
representative compounds for their anti-oxidant and chelating
properties which could be ancillary for the treatment of fungal
infections.
2. Chemistry
We designed thirty-six new derivatives structurally character-
ized by the 1,3-thiazolidin-4-one nucleus presenting at the N1-
hydrazine four different moieties as the chemical requirements
for the antimicrobial effect: an aliphatic chain (C3), a five-
membered cycloaliphatic ring (cyclopentane), a five-membered
aromatic ring (thiophene), and a six-membered heteroaromatic
nucleus (pyridine). These substituents were chosen on the basis of
the best antifungal activity registered for this scaffold as previously
reported [23].
The general synthesis of the target molecules is outlined in
Scheme 1. Selected carbonyl compounds reacted directly with thi-
osemicarbazide in ethanol using acetic acid as the catalyst. The
resulting thiosemicarbazones reacted with ethyl bromoacetate in
methanol and sodium acetate in order to obtain the 1,3-thiazolidin-
4-one derivatives [25,26]. Then, the reaction between the thiazo-
lidinones and 2-/3-nitrobenzyl bromide, 2-/3-/4-chlorobenzyl
bromide and 2-/3-/4-fluorobenzyl bromide in anhydrous acetone
and potassium carbonate gave the N-functionalized thiazolidinone
derivatives (1e32). 4-Aminobenzyl derivatives (33e36) were ob-
tained by the reduction of N-substituted-4-thiazolidinones bearing
a para-nitrobenzyl at lactam nitrogen [23]; sodium dithionite was
previously solubilized in a basic aqueous solution and added
dropwise to a stirring suspension of the 4-nitrobenzyl compounds
in tetrahydrofuran at room temperature. All the synthesized com-
pounds were purified by column chromatography before charac-
terization by spectroscopic methods (IR and 1H and 13C NMR) and
elemental analysis to ensure their purity.
3. Antibacterial and anti-Candida activities
Firstly, derivatives 1e36, dissolved in dimethylsulfoxide
(DMSO), were evaluated for their antibacterial activity. Organisms
from routine clinical Gram-positive (Staphylococcus aureus,Scheme 1. Synthesis of derivatives 1e36. Reagents and conditions: (i) EtOH, acetic acid (cat.)
NO2 substituted: Na2S2O4, NaHCO3, water, THF, rt.Staphylococcus warneri, Streptococcus faecalis, Streptococcus a-
hemolyticus) and Gram-negative isolates (Escherichia coli, Proteus
mirabilis, Enterobacter spp., Klebsiella oxytoca) from the respiratory
tract were carefully collected from specimens of patients at the
Hospital ‘Azienda Policlinico Umberto I’ (Sapienza University of
Rome, Italy). The isolates were subcultured on a qualified medium
to ensure purity. The isolates were identified by conventional
methodologies; all isolates were subcultured to ensure optimal
growth. The in vitro antibacterial activities of the compounds were
determined by the broth microdilution method with Mueller-
Hinton II broth (BBL Microbiology Systems, Cockeysville, MD), as
strictly recommended by the National Committee for Clinical Lab-
oratory Standards (NCCLS) [27].
Once verified the absence of antibacterial effects, their anti-
fungal activity was evaluated against twenty-two clinical fungal
isolates of Candida spp. (C. albicans, C. glabrata, C. tropicalis, C. krusei,
C. parapsilosis and C. sake) and compared with six topical and sys-
temic reference drugs clotrimazole, fluconazole, ketoconazole,
miconazole, tioconazole and amphotericin B (Table 1). The used
clinical isolates were recently collected from specimens of patients
at the ‘Azienda Policlinico Umberto I’ (Sapienza University of
Rome) and were obtained from haematology/oncology and surgery
departments, which also included an intensive care unit. In
particular, the samples were isolated from the upper and lower
respiratory tract, blood, and indwelling venous catheters; the iso-
lates were identified by conventional methodologies. Prior to
testing, each isolate was subcultured on a qualified medium to
ensure purity and optimal growth. All derivatives were dissolved in
DMSO. The in vitro antifungal activities were determined by the
broth microdilution method with Sabouraud dextrose broth (BBL
Microbiology Systems, Cockeysville, MD) as recommended by the
NCCLS [28].
4. Cell toxicity
Compounds 3, 5, 10, 11, 15, 19, 20, 27, 28, 30 and 33, endowed
with the strongest antifungal effect against Candida spp., were also
assayed at five concentrations ranging from 0.05 to 100 mg/mL to
evaluate their cytotoxic activity against a cultured cell line derived
from a human laryngeal epidermoid carcinoma (Hep2) with
respect to the reference drug (clotrimazole), as reported in Table 2.
Cell viability was analyzed using Trypan Blue exclusion test [29].
5. Anti-oxidant and metal chelating assays
A large number of the most representative derivatives were also
tested for their anti-oxidant and chelating properties in order to
assess ancillary activities which could be useful to obtain multi-
target agents against Candida infections (Table 3). The chelating, rt; (ii) MeOH, CH3COONa, rt; (iii) anhydrous acetone, anhydrous K2CO3, reflux; (iv) if 4-
Table 1
Minimal inhibitory concentration (MIC) expressed as geometric mean of derivatives 1e36 and reference compounds against twenty-two clinical strains of Candida species.
Compound Structure Tested fungi (MIC mg/mL)
C. albicans (8) C. glabrata (4) C. tropicalis (3) C. krusei (3) C. parapsilosis (2) C. sake (2)
1 2 4 8 2 16 4
2 4 2 8 4 16 4
3 2 2 4 2 8 2
4 2 2 4 4 16 2
5 2 2 2 2 16 2
6 4 16 4 8 4 2
7 4 2 4 2 8 4
8 4 2 8 8 8 4
9 8 2 4 8 4 8
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Table 1 (continued )
Compound Structure Tested fungi (MIC mg/mL)
C. albicans (8) C. glabrata (4) C. tropicalis (3) C. krusei (3) C. parapsilosis (2) C. sake (2)
10 2 2 2 8 2 2
11 2 4 2 4 4 2
12 4 8 4 4 4 8
13 4 4 4 4 2 8
14 4 2 16 2 4 8
15 2 8 2 2 2 2
16 2 2 8 8 2 4
17 8 4 16 16 2 8
18 8 4 16 8 2 8
(continued on next page)
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Table 1 (continued )
Compound Structure Tested fungi (MIC mg/mL)
C. albicans (8) C. glabrata (4) C. tropicalis (3) C. krusei (3) C. parapsilosis (2) C. sake (2)
19 2 2 2 2 4 8
20 2 2 2 8 4 2
21 2 2 16 8 8 2
22 2 4 4 8 8 2
23 4 4 2 8 8 8
24 4 4 2 4 8 4
25 8 4 2 2 4 4
26 4 4 8 16 4 2
27 2 2 2 2 2 2
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Table 1 (continued )
Compound Structure Tested fungi (MIC mg/mL)
C. albicans (8) C. glabrata (4) C. tropicalis (3) C. krusei (3) C. parapsilosis (2) C. sake (2)
28 2 2 2 4 2 16
29 4 2 8 8 2 4
30 2 2 2 8 2 4
31 4 2 8 8 4 8
32 8 4 8 8 4 8
33 4 1 32 2 2 4
34 2 16 32 16 64 256
35 4 8 2 8 8 2
36 2 8 2 8 8 2
Fluconazole 2 2 2 2 2 2
(continued on next page)
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Table 1 (continued )
Compound Structure Tested fungi (MIC mg/mL)
C. albicans (8) C. glabrata (4) C. tropicalis (3) C. krusei (3) C. parapsilosis (2) C. sake (2)
Ketoconazole 2 2 2 4 2 4
Clotrimazole 2 2 2 2 2 2
Miconazole 2 4 2 4 4 2
Tioconazole 8 4 8 8 8 4
Amphotericin B 4 4 2 4 2 2
Table 2
Cytotoxic effect (CC50) of the most active compounds and clotrimazole tested on Hep2 cells after 24 h of incubation at 37 C using Trypan blue exclusion test expressed as cell
survival fraction (%).a
Compound 0.05 mg/mL 0.5 mg/mL 5 mg/mL 10 mg/mL 50 mg/mL CC50 (mg/mL)
3 88.00% 84.00% 74.00% 61.00% 0.00% 20
5 79.00% 68.00% 51.00% 0.00% 0.00% 5
10 82.00% 69.00% 52.00% 37.00% 0.00% 11
11 91.00% 80.00% 62.00% 41.00% 0.00% 15
15 80.00% 68.00% 42.00% 0.00% 0.00% 6
19 83.00% 76.00% 68.00% 52.00% 0.00% 15
20 91.00% 83.00% 70.00% 42.00% 0.00% 16
27 94.00% 89.00% 82.00% 63.00% 0.00% 21
28 94.00% 87.5% 85.00% 69.00% 0.00% 21
30 89.00% 83.00% 59.00% 47.00% 0.00% 16
Clotrimazole 93.00% 93.40% 92.50% 68.00% 10.20% 18
a Cells incubated with culture medium alone represented the controls. Viability with 2 mL of DMSO ¼ 94%, viability with 20 mL of DMSO ¼ 87%. Data represent arithmetic
means of at least three independent experiments.
Table 3
Anti-oxidant and chelating properties of the most active and representative compounds.
Compound Anti-oxidant assays (mM) Chelating activity (mM)
Phosphomolybdenum assay (EC50) FRAP (EC50) CUPRAC (EC50) DPPH (IC50) ABTS (IC50) IC50
3 1.12 ± 0.03 2.40 ± 0.01 2.25 ± 0.02 >5 18.07 ± 1.24 >5
5 1.24 ± 0.02 5.29 ± 0.27 2.35 ± 0.03 >5 19.36 ± 1.59 >5
10 0.70 ± 0.03 5.63 ± 0.17 2.37 ± 0.03 >5 12.43 ± 0.14 >5
11 1.26 ± 0.06 2.13 ± 0.03 2.40 ± 0.04 >5 15.69 ± 0.84 3.84 ± 0.16
15 1.36 ± 0.02 2.62 ± 0.05 2.55 ± 0.02 >5 21.13 ± 2.28 4.64 ± 0.47
19 1.37 ± 0.02 2.02 ± 0.09 1.85 ± 0.14 >5 21.54 ± 3.24 3.90 ± 0.04
20 1.16 ± 0.06 6.22 ± 0.23 1.75 ± 0.02 >5 16.15 ± 0.12 3.67 ± 0.23
27 1.16 ± 0.03 2.32 ± 0.08 1.59 ± 0.01 >5 20.32 ± 3.42 1.64 ± 0.03
28 2.04 ± 0.10 4.93 ± 0.42 1.40 ± 0.06 >5 26.79 ± 2.02 2.76 ± 0.03
30 0.56 ± 0.04 4.80 ± 0.21 2.10 ± 0.10 >5 18.31 ± 1.59 >5
33 1.20 ± 0.01 2.76 ± 0.13 1.77 ± 0.01 >5 2.04 ± 0.04 >5
Trolox 1.13 ± 0.05 0.16 ± 0.01 0.24 ± 0.02 0.40 ± 0.01 0.66 ± 0.02 e
EDTA e e e e e 0.02 ± 0.001
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whereas the anti-oxidant activity has been evaluated by five
experimental and well established procedures with respect to
Trolox as reference compound following the promising data ob-
tained for some thiazolidinone-based compounds by other
research groups [30].
The phosphomolybdenum assay is based on the reduction of
Mo(VI) to green phosphate/Mo(V) by antioxidant compounds,
whereas the free radical scavenging activities were evaluated by
DPPH and ABTS assays. Antioxidant compounds usually interact
with free radicals by electron or hydrogen atom transfer, thus con-
verting them into stable and non-radical molecules. Generally, the
radical scavenging activities followed a similar trend in this scaffold.
Antioxidant properties and reducing power are strongly related by
breaking free radical chain reaction and thus inhibiting lipid per-
oxidation. Reducing power was evaluated by the transformation of
Fe3þ to Fe2þ and Cu2þ to Cuþ in the presence of the tested com-
pounds. By analyzing the data of their metal chelating activity in
Table 3, it is also possible to state the ability of this scaffold in theprevention of reactive oxygen species production. These findings
support that chelation of transition metals is one of the ways
through which thiazolidinones exert their antioxidant activity.6. Results and discussion
A new class of N-functionalized-1,3-thiazolidin-4-one de-
rivatives were easily synthesized in high yields and evaluated
in vitro for their antimicrobial effect against several bacterial and
fungal clinical isolates. None of the products possessed antibacte-
rial activity (MIC >256 mg/mL, see Supplementary material);
consequently the compounds have shown to be effective selectively
against fungal pathogens. As reported in Table 1 for the in vitro
antimycotic activity assay many compounds had good antifungal
effects towards C. albicans and non-albicans spp. with MIC values
that were similar or better than those of reference drugs. Among
the aliphatic derivatives, compound 5, provided with a 3-
nitrobenzyl ring at the lactam NH, was the most active with MIC
values of 2 mg/mL against all the species, except for C. parapsilosis,
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substituent, was active against C. krusei and C. parapsilosis
(MICs ¼ 2 mg/mL) and especially against C. glabrata (MIC ¼ 1 mg/
mL). Also the cyclopentane derivative 10, bearing a fluorine at C2 of
the benzyl ring, was very active against C. albicans, C. glabrata,
C. tropicalis, C. parapsilosis and C. sake (MICs ¼ 2 mg/mL), whereas
the 4-chlorobenzyl compound 30 was very effective against
C. albicans, C. glabrata, C. tropicalis and C. parapsilosis (MICs ¼ 2 mg/
mL). Among the thiophene derivatives, compounds 3, 11, 15 and 19
possessed a MIC of 2 mg/mL against C. albicans and compound 27, in
which the benzyl group was functionalized with a chlorine in the
meta position, was shown to be very active against all the tested
fungal species (MIC¼ 2 mg/mL). Finally, for the pyridine derivatives,
we found that compounds 20 and 28, with a 4-fluoro and 3-
chlorobenzyl groups at the lactam nitrogen respectively, dis-
played MIC values of 2 mg/mL against most of Candida species. With
respect to the previous series of thiazolidinones [23], the intro-
duction of specific electron-withdrawing substituents on the
benzyl group kept the antifungal activity similar to that of reference
drugs.
In consideration of these results, we evaluated the cytotoxic
effects (CC50) by Trypan blue exclusion test at five different
concentrations of the most active derivatives, possessing the
lowest MIC values against C. albicans and other Candida spp. (3, 5,
10, 11, 15, 19, 20, 27, 28, 30 and 33), and of the reference drug
clotrimazole (Table 2). All the selected compounds have proven
to be as cytotoxic as clotrimazole and to display cytotoxicity at
higher concentration than that required for the pharmacological
activity.
Moreover, a large number of compounds displayed similar
antioxidant activity of Trolox in the Phosphomolybdenum assay
with EC50 values in the millimolar range, except for derivatives 10
and 30 both characterized by the cyclopentane ring and a halogen
on the aryl group (EC50 values in the micromolar range). They
resulted less active than the reference compound in the other four
anti-oxidant assays (FRAP, CUPRAC, DPPH and ABTS) showing the
same biological trend. As regards the chelating activity, only few
derivatives were endowed with discrete IC50 values with respect
to EDTA and they highlight the beneficial role of a thiophene ring
in the structure (11, 15, 19 and 27). In conclusion, we synthesized a
new scaffold of N-benzylated thiazolidinone derivatives possess-
ing antimycotic activity against Candida spp. and endowed with
limited cytotoxicity and promising anti-oxidant and chelating
activity.
7. Experimental section
The chemicals, solvents for synthesis, and spectral grade sol-
vents were purchased fromAldrich (Italy) and usedwithout further
purification. Melting points (uncorrected) were determined auto-
matically on an FP62 apparatus (Mettler-Toledo). 1H and 13C NMR
spectra were recorded at 400 and 101 MHz, respectively, on a
Bruker spectrometer using CDCl3 or DMSO-d6 as solvent. Chemical
shifts are expressed as d units (parts per millions) relative to the
solvent peak. Coupling constants J are valued in Hertz (Hz). IR
spectra (neat) were registered on a Perkin Elmer FT-IR Spectrom-
eter Spectrum 1000. Elemental analyses for C, H, and N were
recorded on a PerkineElmer 240 Bmicroanalyzer and the analytical
results were within ±0.4% of the theoretical values for all com-
pounds. All reactions were monitored by TLC performed on 0.2 mm
thick silica gel plates (60 F254 Merck).
In general, the IR spectrum (neat) for derivatives 1e36 showed a
band at about 3027 cm1 (Csp2-H stretching), at about 1693 (C]O
stretching), at about 1622 (C]N stretching), and at about 1582 and
1447 (C]C stretching).7.1. General procedure for the synthesis of compounds 1-36
The initial carbonyl compound (50 mmol) was dissolved/sus-
pended in ethanol (50 mL) and magnetically stirred with thio-
semicarbazide (50 mmol) and catalytic amounts of acetic acid for
8e24 h at room temperature. The obtained thiosemicarbazone was
filtered, washed with appropriate solvent (n-hexane. petroleum
ether or diethyl ether) and dried under vacuum. The intermediate
thiosemicarbazone (50 mmol) reacted with ethyl-bromoacetate
(50 mmol), in methanol (50 mL) and sodium acetate (50 mmol)
at room temperature under magnetic stirring for 24 h. The resulting
4-thiazolidinone was poured on ice, filtered or extracted with
chloroform and purified by column chromatography (SiO2. ethyl
acetate/n-hexane 1/2). Then, the resulting thiazolidinone
(50mmol) was dissolved/suspended in 50mL of anhydrous acetone
in the presence of anhydrous potassium carbonate (50 mmol), and
reacted with equimolar amounts of 2-, 3-nitrobenzyl bromide, 2-,
3-, 4-chlorobenzyl bromide and 2-, 3-, 4-fluorobenzyl bromide for
24e48 h. The products were poured on ice, filtered or extracted
with chloroform (3  50 mL) and purified by column chromatog-
raphy (SiO2. ethyl acetate/n-hexane) in order to obtain the title
compounds in high yields. To obtain 4-aminobenzyl derivatives
(33e36), sodium dithionite (5.5 eq) was solubilized in a solution of
water (30 mL) and sodium bicarbonate (5.5 eq), then the aqueous
solution was added dropwise to a stirring suspension of 4-
nitrobenzyl compounds (1.0 eq) in tetrahydrofuran (50 mL) at
room temperature for 2 h. Then tetrahydrofuran was evaporated in
vacuo and the solid precipitated from the aqueous phase was
filtered and washed with water and petroleum ether to give the
desired amino derivative.
7.1.1. 3-(2-Nitrobenzyl)-2-(2-(propan-2-ylidene)hydrazono)
thiazolidin-4-one (1)
White powder, mp 144e146 C, 91% yield; 1H NMR (400 MHz,
CDCl3): d 1.84 (s, 3H, CH3), 2.03 (s, 3H, CH3), 3.89 (s, 2H, CH2,
thiazolidinone), 5.40 (s, 2H, ArCH2), 7.31 (bs, 1H, Ar), 7.43e7.47 (m,
1H, Ar), 7.56e7.60 (m, 1H, Ar), 8.06e8.08 (d, J ¼ 8.0 Hz, 1H, Ar). 13C
NMR (101 MHz, DMSO-d6) d 18.36 (CH3), 24.95 (CH3), 39.09 (CH2,
Thiaz.), 42.80 (CH2), 125.18 (Ar), 128.67 (Ar), 129.15 (Ar), 131.25 (Ar),
134.44 (Ar), 148.67 (Ar), 159.46 (C]N, Thiaz.), 165.79 (C]N), 172.75
(C]O). Anal. Calcd. for C13H14N4O3S: C, 50.97; H, 4.61; N, 18.29.
Found: C, 50.78; H, 4.30; N, 18.02.
7.1.2. 3-(2-Nitrobenzyl)-2-(2-cyclopentylidenehydrazono)
thiazolidin-4-one (2)
Grey powder, mp 179e180 C, 87% yield; 1H NMR (400 MHz,
DMSO-d6): d 1.74e1.75 (m, 4H, cyclopentane), 2.25e2.27 (m, 2H,
cyclopentane), 2.46e2.47 (m, 2H, cyclopentane), 3.89 (s, 2H, CH2,
thiazolidinone), 5.38 (s, 2H, ArCH2), 7.31e7.33 (m,1H, Ar), 7.43e7.47
(t, 1H, Ar), 7.56e7.60 (t, 1H, Ar), 8.06e8.08 (d, J ¼ 8.8 Hz, 1H, Ar). 13C
NMR (101 MHz, DMSO-d6) d 24.44 (CH2), 24.76 (CH2), 29.86 (CH2),
32.59 (CH2, Thiaz.), 32.97 (CH2), 42.71 (CH2), 125.13 (Ar), 128.80
(Ar), 129.16 (Ar), 131.27 (Ar), 134.44 (Ar), 148.73 (C]N, Thiaz.),
159.22 (C]N), 172.69 (Ar), 178.39 (C]O). Anal. Calcd. for
C15H16N4O3S: C, 54.20; H, 4.85; N,16.86. Found: C, 54.44; H, 4.70; N,
17.08.
7.1.3. 3-(2-Nitrobenzyl)-2-(2-(1-(thiophen-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (3)
Pink powder, mp 150e151 C, 93% yield; 1H NMR (400 MHz,
CDCl3): d 2.26 (s, 3H, CH3), 3.90 (s, 2H, CH2, thiazolidinone), 5.44 (s,
2H, ArCH2), 7.05e7.06 (m, 1H, thiophene), 7.32e7.48 (m, 4H,
thiophene þ Ar), 7.59e7.61 (m, 1H, Ar), 8.07e8.09 (m, 1H, Ar). 13C
NMR (101 MHz, DMSO-d6) d 14.98 (CH3), 32.80 (CH2, Thiaz.), 42.99
(CH2), 125.23 (Ar), 128.20 (Thioph.), 128.88 (Ar), 129.25 (Ar), 129.32
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oph.), 148.75 (Ar), 158.33 (C]N, Thiaz.), 161.96 (C]N), 172.85 (C]
O). Anal. Calcd. for C16H14N4O3S2: C, 51.32; H, 3.77; N, 14.96. Found:
C, 51.65; H, 3.50; N, 15.11.
7.1.4. 3-(2-Nitrobenzyl)-2-(2-(1-(pyridin-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (4)
Grey powder, mp 170e171 C. 86% yield; 1H NMR (400 MHz,
CDCl3): d 2.37 (s, 3H, CH3), 3.94 (s, 2H, CH2, thiazolidinone), 5.50 (s,
2H, ArCH2), 7.35e7.39 (m, 2H, Ar), 7.45e7.50 (m, 1H, Ar), 7.60 (bs,
1H, Ar), 7.76e7.77 (m, 1H, Ar), 8.10e8.12 (m, 1H, Ar), 8.16e8.20 (m,
1H, Ar), 8.65 (bs, 1H, Ar). 13C NMR (101 MHz, DMSO-d6) d 13.72
(CH3), 32.88 (CH2, Thiaz.), 43.13 (CH2), 120.91 (Pyr), 125.13 (Pyr),
125.27 (Ar), 128.87 (Ar), 129.28 (Ar), 131.21 (Ar), 134.51 (Ar), 137.08
(Pyr), 148.73 (Ar), 149.33 (Pyr), 155.32 (Pyr), 162.40 (C]N, Thiaz.),
163.69 (C]N),172.91 (C]O). Anal. Calcd. for C17H15N5O3S: C, 55.27;
H, 4.09; N, 18.96. Found: C, 55.10; H, 4.21; N, 19.12.
7.1.5. 3-(3-Nitrobenzyl)-2-(2-(propan-2-ylidene)hydrazono)
thiazolidin-4-one (5)
White powder, mp 190e191 C, 92% yield; 1H NMR (400 MHz,
CDCl3): d 2.08 (s, 3H, CH3), 2.09 (s, 3H, CH3), 3.82 (s, 2H, CH2,
thiazolidinone), 5.05 (s, 2H, ArCH2), 7.50e7.54 (t, 1H, Ar), 7.80e7.82
(d, J¼ 7.6 Hz,1H, Ar), 8.17e8.19 (d, J¼ 7.6 Hz,1H, Ar), 8.39 (s,1H, Ar).
13C NMR (101 MHz, CDCl3) d 18.83 (CH3), 25.08 (CH3), 32.33 (CH2,
Thiaz.), 45.73 (CH2),123.06 (Ar),124.25 (Ar),129.53 (Ar),135.10 (Ar),
137.60 (Ar), 148.12 (Ar), 158.93 (C]N, Thiaz.), 166.97 (C]N), 171.80
(C]O). Anal. Calcd. for C13H14N4O3S: C, 50.97; H, 4.61; N, 18.29.
Found: C, 50.71; H, 4.88; N, 18.41.
7.1.6. 3-(3-Nitrobenzyl)-2-(2-cyclopentylidenehydrazono)
thiazolidin-4-one (6)
White powder, mp 90e95 C, 90% yield; 1H NMR (400 MHz,
CDCl3): d 1.81e1.85 (m, 4H, cyclopentane), 2.51e2.56 (m, 4H,
cyclopentane), 3.82 (s, 2H, CH2, thiazolidinone), 5.03 (s, 2H, ArCH2),
7.52e7.54 (t, 1H, Ar), 7.81e7.83 (m, 1H, Ar), 8.17e8.19 (m, 1H, Ar),
8.40 (s, 1H, Ar). 13C NMR (101 MHz, CDCl3) d 24.67 (CH2), 24.92
(CH2), 30.53 (CH2), 32.39 (CH2, Thiaz.), 33.44 (CH2), 45.69 (CH2),
123.09 (Ar), 124.25 (Ar), 124.49 (Ar), 129.50 (Ar), 129.57 (Ar), 148.10
(Ar), 158.48 (C]N, Thiaz.), 171.70 (C]N),180.22 (C]O). Anal. Calcd.
for C15H16N4O3S: C, 54.20; H, 4.85; N, 16.86. Found: C, 54.02; H,
4.63; N, 16.59.
7.1.7. 3-(3-Nitrobenzyl)-2-(2-(1-(thiophen-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (7)
Yellow powder, mp 165e170 C, 82% yield; 1H NMR (400 MHz,
DMSO-d6): d 2.36 (s, 3H, CH3), 4.05 (s, 2H, CH2, thiazolidinone), 5.05
(s, 2H, ArCH2), 7.11e7.13 (m, 1H, thiophene), 7.54e7.55 (m, 1H,
thiophene), 7.61e7.62 (m, 1H, thiophene), 7.65e7.69 (m, 1H, Ar),
7.83e7.85 (m, 1H, Ar), 8.17e8.19 (m, 1H, Ar), 8.30 (s, 1H, Ar). 13C
NMR (101 MHz, DMSO-d6) d 15.34 (CH3), 32.71 (CH2, Thiaz.), 45.69
(CH2), 123.14 (Ar), 123.61 (Ar), 128.22 (Thioph.), 129.35 (Thioph.),
130.06 (Thioph.), 130.50 (Ar), 135.34 (Ar), 138.63 (Ar), 143.36 (Thi-
oph.), 148.15 (Ar), 158.39 (C]N, Thiaz.), 162.27 (C]N), 172.73 (C]
O). Anal. Calcd. for C16H14N4O3S2: C, 51.32; H, 3.77; N, 14.96. Found:
C, 51.19; H, 3.95; N, 15.16.
7.1.8. 3-(3-Nitrobenzyl)-2-(2-(1-(pyridin-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (8)
Grey powder, mp 195e200 C, 94% yield; 1H NMR (400 MHz,
DMSO-d6): d 2.42 (s, 3H, CH3), 4.10 (s, 2H, CH2, thiazolidinone), 5.09
(s, 2H, ArCH2), 7.45 (bs, 1H, Ar), 7.68 (bs, 1H, Ar), 7.86e7.88 (m, 2H,
Ar), 8.05e8.07 (m, 1H, Ar), 8.17e8.19 (m, 1H, Ar), 8.32 (s, 1H, Ar),
8.64 (s, 1H, Ar). 13C NMR (101 MHz, DMSO-d6) d 14.05 (CH3), 32.77
(CH2, Thiaz.), 45.79 (CH2), 120.95 (Pyr), 123.18 (Ar), 123.57 (Ar),125.15 (Pyr), 130.54 (Ar), 135.40 (Ar), 137.13 (Pyr), 138.57 (Ar),
148.20 (Ar), 149.37 (Pyr), 155.34 (Pyr), 163.72 (C]N, Thiaz.), 164.08
(C]N), 172.83 (C]O). Anal. Calcd. for C17H15N5O3S: C, 55.27; H,
4.09; N, 18.96. Found: C, 55.44; H, 4.32; N, 19.20.
7.1.9. 3-(2-Fluorobenzyl)-2-(2-(propan-2-ylidene)hydrazono)
thiazolidin-4-one (9)
Yellow powder, mp 73e75 C, 93% yield; 1H NMR (400 MHz,
CDCl3): d 1.99 (s, 3H, CH3), 2.16 (s, 3H, CH3), 3.87 (s, 2H, CH2, thia-
zolidinone), 5.06 (s, 2H, ArCH2), 7.05e7.11 (m, 2H, Ar), 7.29e7.32 (m,
2H, Ar). 13C NMR (101 MHz, DMSO-d6) d 18.54 (CH3), 24.93 (CH3),
32.35 (CH2, Thiaz.), 39.10 (CH2), 110.00 (Ar), 115.70 (d, JC-F¼ 29.3 Hz,
Ar), 123.33 (d, JC-F ¼ 20.0 Hz, Ar), 124.83 (Ar), 129.91 (d, JC-
F ¼ 13.3 Hz, Ar), 159.55 (C]N, Thiaz.), 165.73 (C]N), 172.43 (C]O).
Anal. Calcd. for C13H14FN3OS: C, 55.90; H, 5.05; N, 15.04. Found: C,
55.72; H, 4.78; N, 15.22.
7.1.10. 3-(2-Fluorobenzyl)-2-(2-cyclopentylidenehydrazono)
thiazolidin-4-one (10)
Brown oil, 64% yield; 1H NMR (400 MHz, CDCl3): d 1.76e1.80 (m,
4H, cyclopentane), 2.42e2.45 (m, 2H, cyclopentane), 2.56e2.57 (m,
2H, cyclopentane), 3.86 (s, 2H, CH2, thiazolidinone), 5.06 (s, 2H,
ArCH2), 7.03e7.11 (m, 2H, Ar), 7.27e7.35 (m, 2H, Ar). 13C NMR
(101 MHz, DMSO-d6) d 24.34 (CH2), 24.89 (CH2), 30.32 (CH2), 32.66
(CH2, Thiaz.), 33.16 (CH2), 45.55 (CH2), 114.23 (d, JC-F ¼ 20.9 Hz, Ar),
115.12 (d, JC-F¼ 23.1 Hz, Ar), 123.89 (d, JC-F¼ 2.8 Hz, Ar), 130.43 (Ar),
139.11 (Ar), 158.11 (C]N, Thiaz.), 160.14 (C]N), 162.09 (d, JC-
F ¼ 244.7 Hz, Ar), 172.50 (C]O). Anal. Calcd. for C15H16FN3OS: C,
59.00; H, 5.28; N, 13.76. Found: C, 59.25; H, 5.04; N, 13.99.
7.1.11. 3-(2-Fluorobenzyl)-2-(2-(1-(thiophen-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (11)
Orange powder, mp 83e85 C, 91% yield; 1H NMR (400 MHz,
DMSO-d6): d 2.28 (s, 3H, CH3), 4.06 (s, 2H, CH2, thiazolidinone), 4.98
(s, 2H, ArCH2), 7.10e7.21 (m, 3H, thiophene), 7.33e7.36 (m, 2H, Ar),
7.51e7.52 (m, 1H, Ar), 7.61e7.62 (m, 1H, Ar). 13C NMR (101 MHz,
DMSO-d6) d 15.15 (CH3), 32.60 (CH2, Thiaz.), 115.76 (d, JC-F¼ 21.2 Hz,
Ar), 123.26 (d, JC-F ¼ 14.4 Hz, Ar), 124.86 (Ar), 128.19 (Thioph.),
129.24 (Thioph.), 129.94 (Ar), 129.99 (Thioph.), 130.09 (Ar), 143.37
(Ar), 158.27 (C]N, Thiaz.), 160.54 (d, JC-F ¼ 246.7 Hz, Ar), 162.02
(C]N), 172.53 (C]O). Anal. Calcd. for C16H14FN3OS2: C, 55.31; H,
4.06; N, 12.09. Found: C, 55.60; H, 3.83; N, 12.21.
7.1.12. 3-(2-Fluorobenzyl)-2-(2-(1-(pyridin-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (12)
Orange powder, mp 139e141 C, 84% yield; 1H NMR (400 MHz,
CDCl3): d 2.58 (s, 3H, CH3), 3.90 (s, 2H, CH2, thiazolidinone), 5.16 (s,
2H, ArCH2), 7.06e7.14 (m, 2H, Ar), 7.38e7.49 (m, 3H, Ar), 7.91e7.92
(m, 1H, Ar), 8.26e8.29 (m, 1H, Ar), 8.74e8.77 (m, 1H, Ar). 13C NMR
(101 MHz, DMSO-d6) d 13.89 (CH3), 32.64 (CH2, Thiaz.), 39.09 (CH2),
114.90 (d, JC-F ¼ 20.9 Hz, Ar), 115.77 (d, JC-F ¼ 24.6 Hz, Ar), 120.91
(Pyr), 124.98 (d, JC-F ¼ 24.7 Hz, Ar), 130.12 (Pyr), 137.09 (Ar), 139.24
(Ar), 139.24 (Pyr), 149.32 (Pyr), 155. 75 (Pyr), 158.34 (Ar), 158.87
(C]N, Thiaz.), 163.80 (C]N), 172.60 (C]O). Anal. Calcd. for
C17H15FN4OS: C, 59.63; H, 4.42; N, 16.36. Found: C, 59.36; H, 4.13; N,
16.61.
7.1.13. 3-(3-Fluorobenzyl)-2-(2-(propan-2-ylidene)hydrazono)
thiazolidin-4-one (13)
Yellow oil, 68% yield; 1H NMR (400 MHz, CDCl3): d 2.06 (s, 3H,
CH3), 2.14 (s, 3H, CH3), 3.81 (s, 2H, CH2, thiazolidinone), 4.95 (s, 2H,
ArCH2), 6.97e7.01 (m, 1H, Ar), 7.14e7.23 (m, 2H, Ar), 7.26e7.32 (m,
1H, Ar). 13C NMR (101 MHz, DMSO-d6) d 18.64 (CH3), 24.92 (CH3),
32.39 (CH2, Thiaz.), 45.66 (CH2), 114.66 (d, JC-F ¼ 10.8 Hz, Ar), 124.31
(d, JC-F ¼ 3.1 Hz, Ar), 130.68 (d, JC-F ¼ 4.6 Hz, Ar), 139.37 (d, JC-
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165.62 (C]N), 172.56 (C]O). Anal. Calcd. for C13H14FN3OS: C,
55.90; H, 5.05; N, 15.04. Found: C, 55.75; H, 4.82; N, 14.89.
7.1.14. 3-(3-Fluorobenzyl)-2-(2-cyclopentylidenehydrazono)
thiazolidin-4-one (14)
White powder, mp 97e100 C, 95% yield; 1H NMR (400 MHz,
CDCl3): d 1.82e1.83 (m, 4H, cyclopentane), 2.51e2.54 (m, 4H,
cyclopentane), 3.80 (s, 2H, CH2, thiazolidinone), 4.93 (s, 2H, ArCH2),
7.00e7.01 (m, 1H, Ar), 7.18e7.25 (m, 3H, Ar). 13C NMR (101 MHz,
DMSO-d6) d 24.55 (CH2), 24.84 (CH2), 30.34 (CH2), 32.43 (CH2,
Thiaz.), 33.02 (CH2) 45.69 (CH2),114.82 (d, JC-F¼ 21.11 Hz, Ar),115.30
(d, JC-F ¼ 21.9 Hz, Ar), 124.53 (d, JC-F ¼ 2.7 Hz, Ar), 130.82 (d, JC-
F ¼ 8.3 Hz, Ar), 139.33 (d, JC-F ¼ 7.5 Hz, Ar), 158.43 (C]N, Thiaz.),
159.58 (C]N), 162.47 (d, JC-F ¼ 244.5 Hz, Ar), 172.53 (C]O). Anal.
Calcd. for C15H16FN3OS: C, 59.00; H, 5.28; N, 13.76. Found: C, 59.18;
H, 5.47; N, 13.50.
7.1.15. 3-(3-Fluorobenzyl)-2-(2-(1-(thiophen-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (15)
Yellow powder, mp 84e85 C, 89% yield; 1H NMR (400 MHz,
DMSO-d6): d 2.33 (s, 3H, CH3), 4.05 (s, 2H, CH2, thiazolidinone), 4.93
(s, 2H, ArCH2), 7.12e7.22 (m, 4H, thiopheneþ Ar), 7.38e7.41 (m,1H,
Ar), 7.53 (bs, 1H, Ar), 7.61e7.63 (m, 1H, Ar). 13C NMR (101 MHz,
DMSO-d6) d 15.301 (CH3), 32.66 (CH2, Thiaz), 45.84 (CH2), 114.75
(Ar), 115.02 (Ar), 124.13 (Ar), 124.35 (Ar), 128.20 (Thioph.), 129.25
(Thioph.), 130.00 (Thioph.), 130.84 (Ar), 139.35 (Ar), 143.39 (Thi-
oph.), 158.24 (C]N, Thiaz.), 162.26 (C]N), 162.54 (d, JC-
F ¼ 245.0 Hz, Ar), 172.72 (C]O). Anal. Calcd. for C16H14FN3OS2: C,
55.31; H, 4.06; N, 12.09. Found: C, 55.56; H, 3.79; N, 11.84.
7.1.16. 3-(3-Fluorobenzyl)-2-(2-(1-(pyridin-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (16)
Orange powder, mp 130e132 C, 80% yield; 1H NMR (400 MHz,
CDCl3): d 2.64 (s, 3H, CH3), 3.86 (s, 2H, CH2, thiazolidinone), 5.05 (s,
2H, ArCH2), 7.00e7.03 (m, 1H, Ar), 7.20e7.35 (m, 3H, Ar), 7.44e7.46
(m, 1H, Ar), 7.87e7.88 (m, 1H, Ar), 8.25e8.27 (m, 1H, Ar), 8.74e8.76
(m,1H, Ar). 13C NMR (101MHz, DMSO-d6) d 14.03 (CH3), 32.71 (CH2,
Thiaz.), 45.94 (CH2), 114.90 (d, 2JC-F ¼ 20.91 Hz, Ar), 115.18 (d, JC-
F ¼ 21.8 Hz, Ar), 120.95 (Pyr), 124.41 (d, JC-F ¼ 2.6 Hz, Ar), 125.10
(Pyr), 130.90 (d, JC-F¼ 8.3 Hz, Ar), 139.24 (d, JC-F¼ 7.6 Hz, Ar), 139.24
(Pyr), 149.32 (Pyr), 155.375 (Pyr), 162.56 (d, JC-F ¼ 244.4 Hz, Ar),
162.77 (C]N, Thiaz.), 163.57 (C]N), 172.80 (C]O). Anal. Calcd. for
C17H15FN4OS: C, 59.63; H, 4.42; N,16.36. Found: C, 59.90; H, 4.67; N,
16.08.
7.1.17. 3-(4-Fluorobenzyl)-2-(2-(propan-2-ylidene)hydrazono)
thiazolidin-4-one (17)
Yellow powder, mp 78e80 C, 92% yield; 1H NMR (400 MHz,
DMSO-d6): d 1.94 (s, 3H, CH3), 1.96 (s, 3H, CH3), 3.98 (s, 2H, CH2,
thiazolidinone), 4.83 (s, 2H, ArCH2), 7.14e7.19 (m, 2H, Ar), 7.37e7.41
(m, 2H, Ar). 13C NMR (101 MHz, DMSO-d6) d 18.80 (CH3), 24.99
(CH3), 32.35 (CH2, Thiaz.), 45.46 (CH2), 115.60 (d, JC-F ¼ 27.7 Hz, Ar),
130.60 (d, JC-F ¼ 10.8 Hz, Ar), 132.90 (Ar), 160.15 (d, JC-F ¼ 44.7 Hz,
Ar), 163.59 (C]N, Thiaz.), 165.65 (C]N), 172.58 (C]O). Anal. Calcd.
for C13H14FN3OS: C, 55.90; H, 5.05; N, 15.04. Found: C, 55.68; H,
5.24; N, 15.17.
7.1.18. 3-(4-Fluorobenzyl)-2-(2-cyclopentylidenehydrazono)
thiazolidin-4-one (18)
White powder, mp 79e81 C, 90% yield; 1H NMR (400 MHz,
DMSO-d6): d 1.71 (bs, 4H, cyclopentane), 2.37e2.39 (m, 4H, cyclo-
pentane), 3.98 (s, 2H, CH2, thiazolidinone), 4.81 (s, 2H, ArCH2),
7.15e7.19 (m, 2H, Ar), 7.39e7.42 (m, 2H, Ar). 13C NMR (101 MHz,
DMSO-d6) d 24.60 (CH2), 24.86 (CH2), 30.41 (CH2), 32.39 (CH2,Thiaz.), 33.06 (CH2), 45.49 (CH2), 115.54 (d, JC-F¼ 21.5 Hz, Ar), 115.59
(d, JC-F ¼ 21.5 Hz, Ar), 130.68 (d, JC-F ¼ 8.4 Hz, Ar), 130.87 (d, JC-
F ¼ 8.4 Hz, Ar), 132.85 (d, JC-F ¼ 3.1 Hz, Ar), 158.58 (C]N, Thiaz.),
159.69 (C]N), 162.04 (d, JC-F ¼ 244.8 Hz, Ar), 172.50 (C]O). Anal.
Calcd. for C15H16FN3OS: C, 59.00; H, 5.28; N, 13.76. Found: C, 58.81;
H, 5.49; N, 13.54.
7.1.19. 3-(4-Fluorobenzyl)-2-(2-(1-(thiophen-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (19)
Pink powder, mp 137e138 C, 80% yield; 1H NMR (400 MHz,
CDCl3): d 2.47 (s, 3H, CH3), 3.81 (s, 2H, CH2, thiazolidinone), 5.00 (s,
2H, ArCH2), 6.93e7.08 (m, 3H, thiophene), 7.22e7.52 (m, 4H, Ar). 13C
NMR (101 MHz, DMSO-d6) d 15.37 (CH3), 32.58 (CH2, Thiaz.), 45.62
(CH2), 110.00 (Ar), 115.64 (d, JC-F ¼ 29.3 Hz, Ar), 128.20 (Thioph.),
129.25 (Thioph.), 130.00 (Ar), 130.67 (d, JC-F ¼ 61.6 Hz, Ar), 132.75
(Thioph.), 143.36 (Ar), 158.18 (C]N, Thiaz.), 162.34 (C]N), 172.67
(C]O). Anal. Calcd. for C16H14FN3OS2: C, 55.31; H, 4.06; N, 12.09.
Found: C, 55.06; H, 3.91; N, 11.84.
7.1.20. 3-(4-Fluorobenzyl)-2-(2-(1-(pyridin-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (20)
Yellow powder, mp 198e200 C, 92% yield; 1H NMR (400 MHz,
DMSO-d6): d 2.43 (s, 3H, CH3), 4.07 (s, 2H, CH2, thiazolidinone), 4.94
(s, 2H, ArCH2), 7.19 (bs, 2H, Ar), 7.46 (s, 3H, Ar), 7.88 (s, 1H, Ar),
8.06e8.07 (m, 1H, Ar), 8.64e8.66 (m, 1H, Ar). 13C NMR (101 MHz,
DMSO-d6) d 14.12 (CH3), 32.66 (CH2, Thiaz.), 45.77 (CH2), 115.63 (d,
JC-F ¼ 21.5 Hz, Ar), 115.70 (d, JC-F ¼ 21.5 Hz, Ar), 120.94 (Pyr), 125.11
(Pyr), 130.76 (d, JC-F ¼ 8.4 Hz, Ar), 132.75 (d, JC-F ¼ 3.1 Hz, Ar), 137.10
(Pyr), 149.36 (Pyr), 155.41 (Pyr), 162.09 (d, JC-F ¼ 244.6 Hz, Ar),
163.55 (C]N, Thiaz.), 164.12 (C]N), 172.78 (C]O, Thiaz). Anal.
Calcd. for C17H15FN4OS: C, 59.63; H, 4.42; N, 16.36. Found: C, 59.41;
H, 4.24; N, 16.77.
7.1.21. 3-(2-Chlorobenzyl)-2-(2-(propan-2-ylidene)hydrazono)
thiazolidin-4-one (21)
Yellow oil, 70% yield; 1H NMR (400 MHz, DMSO-d6): d 1.79 (s,
3H, CH3), 1.94 (s, 3H, CH3), 4.05 (s, 2H, CH2, thiazolidinone), 4.95 (s,
2H, ArCH2), 7.17e7.19 (m, 1H, Ar), 7.28e7.32 (m, 2H, Ar), 7.46e7.47
(m, 1H, Ar). 13C NMR (101 MHz, DMSO-d6) d 18.54 (CH3), 24.93
(CH3), 32.48 (CH2, Thiaz.), 43.82 (CH2), 127.65 (Ar), 128.08 (Ar),
129.70 (Ar), 132.26 (Ar), 133.57 (Ar), 158.39 (Ar), 159.49 (C]N,
Thiaz.), 165.70 (C]N), 172.55 (C]N). Anal. Calcd. for C13H14ClN3OS:
C, 52.79; H, 4.77; N, 14.21. Found: C, 52.51; H, 4.98; N, 14.03.
7.1.22. 3-(2-Chlorobenzyl)-2-(2-cyclopentylidenehydrazono)
thiazolidin-4-one (22)
Grey powder, mp 90e92 C, 93% yield; 1H NMR (400 MHz,
CDCl3): d 1.43e1.83 (m, 4H, cyclopentane), 2.34e2.51 (m, 4H,
cyclopentane), 3.87 (s, 2H, CH2, thiazolidinone), 5.15 (s, 2H, ArCH2),
7.10e7.43 (m, 4H, Ar). 13C NMR (101 MHz, DMSO-d6) d 24.46 (CH2),
24.78 (CH2), 30.17 (CH2), 32.50 (CH2, Thiaz.), 32.97 (CH2), 43.79
(CH2) 127.67 (Ar), 128.54 (Ar), 129.39 (Ar), 129.71 (Ar), 132.30 (Ar),
133.43 (Ar), 159.23 (C]N, Thiaz.), 172.49 (C]N), 178.32 (C]O).
Anal. Calcd. for C15H16ClN3OS: C, 55.98; H, 5.01; N, 13.06. Found: C,
56.14; H, 4.87; N, 12.77.
7.1.23. 3-(2-Chlorobenzyl)-2-(2-(1-(thiophen-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (23)
Pink powder, mp 100e102 C, 87% yield; 1H NMR (400 MHz,
CDCl3): d 2.31 (s, 3H, CH3), 3.90 (s, 2H, CH2, thiazolidinone), 5.18 (s,
2H, ArCH2), 7.05e7.06 (m, 1H, thiophene), 7.22 (bs, 3H,
thiophene þ Ar), 7.36e7.41 (m, 3H, Ar). 13C NMR (101 MHz, DMSO-
d6) d 15.12 (CH3), 32.68 (CH2, Thiaz.), 43.99 (CH2), 127.76 (Ar), 128.17
(Ar), 128.25 (Ar), 129.25 (Thioph.), 129.48 (Ar), 129.77 (Thioph.),
132.27 (Thioph.), 133.40 (Ar), 143.29 (Ar), 158.25 (Thioph.), 160.68
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C16H14ClN3OS2: C, 52.81; H, 3.88; N, 11.55. Found: C, 52.66; H, 3.63;
N, 11.24.
7.1.24. 3-(2-Chlorobenzyl)-2-(2-(1-(pyridin-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (24)
Grey powder, mp 149e151 C, 93% yield; 1H NMR (400 MHz,
CDCl3): d 2.42 (s, 3H, CH3), 3.93 (s, 2H, CH2, thiazolidinone), 5.22 (s,
2H, ArCH2), 7.24e7.32 (m, 4H, Ar), 7.40e7.41 (m, 1H, Ar), 7.73 (bs,
1H, Ar), 8.18e8.19 (m, 1H, Ar), 8.63 (bs, 1H, Ar). 13C NMR (101 MHz,
DMSO-d6) d 13.91 (CH3), 32.77 (CH2, Thiaz.), 44.13 (CH2), 120.92
(Pyr), 125.10 (Pyr), 127.79 (Ar), 128.57 (Ar), 129.53 (Ar), 129.83 (Ar),
132.33 (Ar), 133.37 (Ar), 137.07 (Pyr), 149.32 (Pyr), 155.34 (Pyr),
163.63 (C]N, Thiaz.), 163.70 (C]N), 172.74 (C]O). Anal. Calcd. for
C17H15ClN4OS: C, 56.90; H, 4.21; N, 15.61. Found: C, 56.71; H, 4.39;
N, 15.78.
7.1.25. 3-(3-Chlorobenzyl)-2-(2-(propan-2-ylidene)hydrazono)
thiazolidin-4-one (25)
White powder, mp 90e92 C, 97% yield; 1H NMR (400 MHz,
CDCl3): d 2.13 (s, 6H. 2 CH3), 3.84 (s, 2H, CH2, thiazolidinone), 4.96
(s, 2H, ArCH2), 7.14e7.54 (m, 4H, Ar). 13C NMR (101 MHz, DMSO-d6)
d 18.74 (CH3), 25.00 (CH3), 32.41 (CH2, Thiaz.), 45.66 (CH2), 127.06
(Ar), 127.99 (Ar), 128.34 (Ar), 130.76 (Ar), 133.40 (Ar), 139.06 (Ar),
159.82 (C]N, Thiaz.), 165.70 (C]N), 172.61 (C]N). Anal. Calcd. for
C13H14ClN3OS: C, 52.79; H, 4.77; N, 14.21. Found: C, 52.94; H, 4.53;
N, 14.50.
7.1.26. 3-(3-Chlorobenzyl)-2-(2-cyclopentylidenehydrazono)
thiazolidin-4-one (26)
White powder, mp 121e123 C, 90% yield; 1H NMR (400 MHz,
DMSO-d6): d 1.74e1.75 (m, 4H, cyclopentane), 2.35e2.41 (m, 4H,
cyclopentane), 4.04 (s, 2H, CH2, thiazolidinone), 4.87 (s, 2H, ArCH2),
7.35e7.45 (m, 4H, Ar). 13C NMR (101 MHz, DMSO-d6) d 24.57 (CH2),
24.86 (CH2), 30.41 (CH2), 32.44 (CH2, Thiaz.), 33.03 (CH2), 45.66
(CH2) 127.30 (Ar), 128.03 (Ar), 128.61 (Ar), 130.76 (Ar), 133.34 (Ar),
138.96 (Ar), 159.56 (C]N, Thiaz.), 172.53 (C]O). Anal. Calcd. for
C15H16ClN3OS: C, 55.98; H, 5.01; N, 13.06. Found: C, 55.67; H, 5.19;
N, 13.24.
7.1.27. 3-(3-Chlorobenzyl)-2-(2-(1-(thiophen-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (27)
Pink powder, mp 129e131 C, 89% yield; 1H NMR (400 MHz,
CDCl3): d 2.26 (s, 3H, CH3), 3.62 (s, 2H, CH2, thiazolidinone), 4.78 (s,
2H, ArCH2), 6.85e6.88 (m, 1H, thiophene), 7.05e7.08 (m, 3H,
thiophene þ Ar), 7.17e7.20 (m, 2H, Ar), 7.31 (s, 1H, Ar). 13C NMR
(101 MHz, DMSO-d6) d 15.34 (CH3), 32.66 (CH2, Thiaz.), 45.81 (CH2),
127.13 (Ar), 128.06 (Ar), 128.21 (Thioph.), 128.44 (Ar), 129.29 (Thi-
oph.), 130.03 (Thioph.), 130.80 (Ar), 133.44 (Ar), 138.95 (Ar), 143.38
(Thioph.), 158.26 (C]N, Thiaz.), 162.24 (C]N), 172.71 (C]O). Anal.
Calcd. for C16H14ClN3OS2: C, 52.81; H, 3.88; N, 11.55. Found: C,
52.99; H, 3.69; N, 11.73.
7.1.28. 3-(3-Chlorobenzyl)-2-(2-(1-(pyridin-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (28)
Grey powder, mp 147e149 C, 83% yield; 1H NMR (400 MHz,
CDCl3): d 2.59 (s. 3H, CH3), 3.86 (s, 2H, CH2, thiazolidinone), 5.03 (s,
2H, ArCH2), 7.25e7.41 (m, 4H, Ar), 7.48e7.56 (m, 1H, Ar), 7.70e7.76
(m, 1H, Ar), 8.15e8.21 (m, 1H, Ar), 8.61e8.66 (m, 1H, Ar). 13C NMR
(101 MHz, DMSO-d6) d 14.06 (CH3), 32.72 (CH2, Thiaz.), 45.91 (CH2),
120.95 (Pyr), 125.11 (Pyr), 127.19 (Ar), 128.10 (Ar), 128.46 (Ar),
130.82 (Ar), 133.46 (Ar), 137.08 (Pyr), 138.87 (Ar), 149.34 (Pyr),
155.37 (Pyr), 163.60 (C]N, Thiaz.), 164.02 (C]N), 172.80 (C]O).
Anal. Calcd. for C17H15ClN4OS: C, 56.90; H, 4.21; N, 15.61. Found: C,
56.65; H, 4.07; N, 15.37.7.1.29. 3-(4-Chlorobenzyl)-2-(2-(propan-2-ylidene)hydrazono)
thiazolidin-4-one (29)
White powder, mp 103e105 C, 90% yield; 1H NMR (400 MHz,
CDCl3): d 1.66 (s, 3H, CH3), 2.07 (s, 3H, CH3), 3.81 (s, 2H, CH2,
thiazolidinone), 4.95 (s, 2H, ArCH2), 7.22e7.47 (m, 4H, Ar). 13C NMR
(101 MHz, CDCl3) d 18.83 (CH3), 25.04 (CH3), 32.35 (CH2, Thiaz.),
45.88 (CH2), 128.57 (Ar), 130.35 (Ar), 134.27 (Ar), 145.24 (Ar), 159.08
(C]N, Thiaz.), 166.48 (C]N), 171.89 (C]O). Anal. Calcd. for
C13H14ClN3OS: C, 52.79; H, 4.77; N, 14.21. Found: C, 52.46; H, 4.59;
N, 14.10.
7.1.30. 3-(4-Chlorobenzyl)-2-(2-cyclopentylidenehydrazono)
thiazolidin-4-one (30)
Grey powder, mp 79e81 C, 96% yield; 1H NMR (400 MHz,
DMSO-d6): d 1.71 (m, 4H, cyclopentane), 2.37 (m, 4H, cyclo-
pentane), 3.99 (s, 2H, CH2, thiazolidinone), 5.21 (s, 2H, ArCH2),
7.35e7.40 (m, 4H, Ar). 13C NMR (101 MHz, DMSO-d6) d 24.58 (CH2),
24.84 (CH2), 30.39 (CH2), 32.39 (CH2, Thiaz.), 33.03 (CH2), 45.51
(CH2), 128.78 (Ar), 130.54 (Ar), 132.53 (Ar), 135.55 (Ar), 159.64 (C]
N, Thiaz.), 172.49 (C]N), 178.19 (C]O). Anal. Calcd. for
C15H16ClN3OS: C, 55.98; H, 5.01; N, 13.06. Found: C, 56.16; H, 4.82;
N, 12.84.
7.1.31. 3-(4-Chlorobenzyl)-2-(2-(1-(thiophen-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (31)
White powder, mp 149e151 C, 81% yield; 1H NMR (400 MHz,
DMSO-d6): d 2.34 (s, 3H, CH3), 4.03 (s, 2H, CH2, thiazolidinone), 4.90
(s, 2H, ArCH2), 7.12 (bs,1H, thiophene), 7.41 (bs, 4H, Ar), 7.54 (bs,1H,
thiophene), 7.61e7.62 (m, 1H, thiophene). 13C NMR (101 MHz,
slightly soluble in DMSO-d6) d 15.37 (CH3), 32.61 (CH2, Thiaz.),
45.66 (CH2), 128.22 (Ar), 128.86 (Thioph.), 129.28 (Ar), 130.03
(Thioph.), 130.35 (Thioph.), 130.80 (Ar), 132.67 (Ar), 135.48 (Ar),
143.36 (Thioph.), 158.24 (C]N, Thiaz.), 162.28 (C]N), 172.70 (C]
O). Anal. Calcd. for C16H14ClN3OS2: C, 52.81; H, 3.88; N, 11.55.
Found: C, 53.05; H, 4.02; N, 11.32.
7.1.32. 3-(4-Chlorobenzyl)-2-(2-(1-(pyridin-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (32)
Grey powder, mp 202e204 C, 94% yield; 1H NMR (400 MHz,
DMSO-d6): d 2.41 (s, 3H, CH3), 4.08 (s, 2H, CH2, thiazolidinone), 4.94
(s, 2H, ArCH2), 7.43 (s, 5H, Ar), 7.86e7.88 (m, 1H, Ar), 8.05e8.07 (m,
1H, Ar), 8.64 (m, 1H, Ar). 13C NMR (101 MHz, DMSO-d6) d 14.12
(CH3), 32.68 (CH2, Thiaz.), 45.81 (CH2), 120.94 (Pyr), 125.12 (Pyr),
128.90 (Ar), 130.42 (Ar), 132.74 (Ar), 135.50 (Ar), 137.11 (Pyr), 149.36
(Pyr), 155.39 (Pyr), 163.59 (C]N, Thiaz.), 164.07 (C]N), 172.78 (C]
O). Anal. Calcd. for C17H15ClN4OS: C, 56.90; H, 4.21; N, 15.61. Found:
C, 57.11; H, 3.98; N, 15.94.
7.1.33. 3-(4-Aminobenzyl)-2-(2-(propan-2-ylidene)hydrazono)
thiazolidin-4-one (33)
Yellow powder, mp 166e168 C, 69% yield; 1H NMR (400 MHz,
DMSO-d6): d 1.97 (s, 3H, CH3), 2.00 (s, 3H, CH3), 3.92 (s, 2H, CH2,
thiazolidinone), 4.65 (s, 2H, ArCH2), 5.06 (bs, 2H, NH2, D2O exch.),
6.46e6.48 (d, J¼ 8.4 Hz, 2H, Ar), 7.03e7.05 (d, J¼ 8.4 Hz, 2H, Ar). 13C
NMR (101 MHz, CDCl3) d 18.11 (CH3), 25.43 (CH3), 32.78 (CH2,
Thiaz.), 45.65 (CH2), 125.12 (Ar), 130.88 (Ar), 132.98 (Ar), 134.64
(Ar), 160.68 (C]N, Thiaz.), 166.32 (C]N), 171.12 (C]O). Anal. Calcd.
for C13H16N4OS: C, 56.50; H, 5.84; N, 20.27. Found: C, 56.35; H, 5.61;
N, 20.04.
7.1.34. 3-(4-Aminobenzyl)-2-(2-cyclopentylidenehydrazono)
thiazolidin-4-one (34)
Yellow powder, mp 208e210 C, 71% yield; 1H NMR (400 MHz,
CDCl3): d 1.79e1.87 (m, 4H, cyclopentane), 2.47e2.51 (t, 2H,
cyclopentane), 2.53e2.59 (t, 2H, cyclopentane), 3.66 (bs, 2H, NH2,
D. Secci et al. / European Journal of Medicinal Chemistry 117 (2016) 144e156 155D2O exch.), 3.74 (s, 2H, CH2, thiazolidinone), 4.84 (s, 2H, ArCH2),
6.61e6.63 (d, J¼ 8.4 Hz, 2H, Ar), 7.30e7.32 (d, J¼ 8.4 Hz, 2H, Ar). 13C
NMR (101 MHz, DMSO-d6) d 24.61 (CH2), 24.89 (CH2), 30.50 (CH2),
32.30 (CH2, Thiaz.), 33.03 (CH2), 46.03 (CH2), 113.80 (Ar), 123.49
(Ar), 130.11 (Ar), 148.72 (C]N, Thiaz.), 159.92 (C]N), 172.44 (Ar),
177.97 (C]O). Anal. Calcd. for C15H18N4OS: C, 59.58; H, 6.00; N,
18.53. Found: C, 59.31; H, 5.74; N, 18.32.
7.1.35. 3-(4-Aminobenzyl)-2-(2-(1-(thiophen-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (35)
Yellow powder, mp 163e165 C, 70% yield; 1H NMR (400 MHz,
DMSO-d6): d 2.42 (s, 3H, CH3), 3.97 (s, 2H, CH2, thiazolidinone), 4.72
(s, 2H, ArCH2), 5.06 (bs, 2H, NH2, D2O exch.), 6.49e6.51 (d,
J ¼ 8.0 Hz, 2H, Ar), 7.07e7.09 (d, J ¼ 8.0 Hz, 2H, Ar), 7.12 (bs, 1H,
thiophene), 7.55 (bs, 1H, thiophene), 7.61e7.62 (m, 1H, thiophene).
13C NMR (101 MHz, DMSO-d6) d 15.45 (CH3), 32.51 (CH2, Thiaz.),
46.26 (CH2), 113.93 (Ar), 123.47 (Ar), 128.20 (Thioph.), 129.14 (Thi-
oph.), 129.93 (Ar), 143.53 (Thioph.), 148.78 (Ar), 157.93 (C]N,
Thiaz.), 162.61 (C]N), 172.66 (C]O). Anal. Calcd. for C16H16N4OS2:
C, 55.79; H, 4.68; N, 16.27. Found: C, 55.61; H, 4.37; N, 16.45.
7.1.36. 3-(4-Aminobenzyl)-2-(2-(1-(pyridin-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (36)
Green powder, mp 197e198 C, 72% yield; 1H NMR (400 MHz,
CDCl3): d 2.62 (s, 3H, CH3), 3.71 (bs, 2H, NH2, D2O exch.), 3.79 (s, 2H,
CH2, thiazolidinone), 4.95 (s, 2H, ArCH2), 6.64e6.66 (d, J ¼ 8.0 Hz,
2H, Ar), 7.39e7.40 (m, 3H, Ar), 7.72e7.75 (m, 1H, Ar), 8.20e8.22 (d,
J¼ 7.6 Hz,1H, Ar), 8.65e8.66 (m,1H, Ar). 13C NMR (101MHz, DMSO-
d6) d 14.16 (CH3), 32.54 (CH2, Thiaz.), 46.34 (CH2), 113.89 (Pyr),
120.89 (Pyr), 123.33 (Ar), 125.06 (Ar), 130.00 (Ar), 137.08 (Ar),
148.81 (Pyr),149.33 (Pyr),155.43 (Pyr),163.23 (C]N, Thiaz.), 164.43
(C]N),172.73 (C]O). Anal. Calcd. for C17H17N5OS: C, 60.16; H, 5.05;
N, 20.63. Found: C, 60.38; H, 5.26; N, 20.80.
7.2. Antibacterial activity
Microtiter plates containing serial dilutions of each compound
ranging from 256 to 0.5 mg/mL were inoculated with each organism
to yield the appropriate density (105/mL) in a 100 mL final volume;
each plate included positive controls (bacteria without the com-
pound), and a negative control (medium only). The plates were
incubated for 18e22 h at 35 C. The minimum inhibitory concen-
tration (MIC) for all isolates was defined as the lowest concentra-
tion of antibacterial agent that completely inhibited the growth of
the organism, as detected by the unaided eye.
7.3. Antifungal activity
Microtiter plates containing serial dilutions of each compound
were inoculated with each organism to yield the appropriate
density (103/mL) in a 100 mL final volume; each plate included
positive controls (fungi without a compound) and a negative con-
trol (medium only). The plates were incubated for 24 h at 37 C. The
MIC for all isolates was defined as the lowest concentration of
antifungal agents that completely inhibited the growth of the or-
ganism, as detected by unaided eye.
7.4. Cytotoxicity assay
The Hep2 cell line, delivered from a human epidermoid carci-
noma of the larynx and purchased from a Korean Cell Line Bank
(KCLB No. 10023), was a kind gift by Prof. R. Misasi (Department of
Experimental Medicine-Sapienza University of Rome). Cells were
cultured in Dulbecco's modified eagle media (DMEM), supple-
mented with 10% fetal bovine serum (FBS; Gibco, USA) and 1%streptomycin-penicillin. Cell lines were maintained as adherent
type cultures under humidified atmosphere in 5% CO2 at 37 C in
Dulbecco's modified Eagle's culture medium. Experiments were
performed on cells grown to 60e70% confluency. The stock solu-
tions of the investigated compoundswere prepared in sterile DMSO
and successive dilutions were made in culture medium; the per-
centage of DMSO present in culture medium never exceeded 0.5%.
Hep2 cells in the exponential phase of growth (1  105/mL) were
seeded into 24-well microplate and incubated for 24 h with five
different concentrations of the compounds (0.05e100 mg/mL).
Some plates containing cells alone or cells and DMSO represented
the negative controls, whereas cells incubated with 1 mM natrium
nitroprusside represented the positive one. After incubation time,
cells were mechanically scraped off from the plates, resuspended in
fresh medium and incubated for 30 min with gentle shaking at
37 C in atmosphere of 5% CO2 to recover from the eventual stress.
An aliquot was then diluted (1:1) with a solution 0.4% Trypan blue
stain. After few minutes at room temperature, cells were counted
under an optical microscope in a Thoma hemocytometer chamber
by two different operators. On the basis that Trypan blue is a vital
dye and can enter and interact with the cells unless the plasmatic
membrane is damaged, blue stained cells were considered as
having died. Values are expressed as % of viable cells. Cell viability
in control samples was always 97e98%.7.5. Radical scavenging activity: free radical scavenging activity
(DPPH) and ABTS radical cation scavenging ability
The effects of the samples on DPPH (1,1-diphenyl-2-
picrylhydrazyl) and ABTS [2,2 azino-bis(3-ethylbenzothiazoline-6-
sulfonic acid)] cation radicals were estimated according to well
established procedure in the literature [31,32].
DPPH assay: sample solution (1 mL) was added to a 1 mL
methanol solution of DPPH (final concentration of DPPH was
0.2 mM). The sample absorbance was read at 517 nm after incu-
bation for 30 min at room temperature in the dark. The corre-
sponding IC50 value, which is the effective concentration at which
50% of DPPH radicals are scavenged, was calculated for each com-
pounds and trolox (reference standard).
ABTS assay: briefly, a ABTSþ radical cation was produced
directly by reacting 7 mM ABTS solution with 2.45 mM potassium
persulfate and allowing the mixture to stand for 12e16 h in the
dark at the room temperature. Prior to beginning the assay, ABTS
solution was diluted with methanol to obtain an absorbance of
0.700 ± 0.02 at 734 nm. Then, sample solution (1 mL) was added to
the ABTS solution (2 mL) and mixed. The sample absorbance was
read at 734 nm after incubation for 30 min at room temperature
[32]. Trolox is used as a positive control and the IC50 of each com-
pound was then calculated.7.6. Metal chelating activity on ferrous ions
Metal chelating activity on ferrous ions was evaluated by the
method described by Aktumsek et al. [33]. Briefly, the sample so-
lution (2 mL) was added to FeCl2 solution (0.05 mL, 2 mM). The
reaction was initiated by the addition of 5 mM ferrozine (0.2 mL).
Similarly, a blankwas prepared by adding sample solution (2mL) to
FeCl2 solution (0.05 mL, 2 mM) and water (0.2 mL) without ferro-
zine. Then, the sample and blank absorbance were read at 562 nm
after incubation for 10 min at room temperature. The absorbance of
blank was subtracted from that of the sample. EDTA is used as a
positive control and this biological property was expressed as IC50
value for each compound.
D. Secci et al. / European Journal of Medicinal Chemistry 117 (2016) 144e1561567.7. Reducing power: cupric ion reducing (CUPRAC) and ferric
reducing antioxidant power (FRAP) methods
Cupric ion reducing (CUPRAC) method: sample solution (0.5 mL)
was added to the premixed reaction mixture containing CuCl2
(1 mL, 10 mM), neocuproine (1 mL, 7.5 mM) and NH4Ac buffer
(1 mL, 1 M, pH 7.0). Similarly, a blank was prepared by adding the
sample solution (0.5 mL) to the premixed reaction mixture (3 mL)
without CuCl2. Then, the sample and blank absorbancewere read at
450 nm after incubation for 30 min at room temperature [34]. The
EC50, which is the effective concentration at which the absorbance
was 0.5, was calculated for each compound and trolox (reference
standard).
7.8. Ferric reducing antioxidant power (FRAP) method
sample solution (0.1 mL) was added to the premixed FRAP re-
agent (2 mL) containing acetate buffer (0.3 M, pH 3.6), 2,4,6-tris(2-
pyridyl)-s-triazine (TPTZ) (10mM) in 40mMHCl and ferric chloride
(20 mM) in a ratio of 10:1:1 (v:v:v). Then, the sample absorbance
was read at 593 nm after incubation for 30 min at room tempera-
ture [33]. The results were evaluated by using EC50 values.
7.9. Total antioxidant activity by phosphomolybdenum method
Total antioxidant activities were evaluated using the phospho-
molybdenummethod as previously described in the literature [35].
Sample solution (0.2 mL) was combined with 2 mL of the reagent
solution (0.6 M sulfuric acid, 28 mM sodium phosphate and 4 mM
ammonium molybdate). The sample absorbance was read at
695 nm after incubation for 90 min at 95 C. The results were
expressed as EC50 values.
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